| Ident. | Authors (with country if any) | Title |
|---|
| 000009 (2008) |
Misato Hashizume [Japon] ; Masahiko Mihara [Japon] | Influence of humanized anti-IL-6R antibody, tocilizumab on the activity of soluble gp130, natural inhibitor of IL-6 signaling |
| 000010 (2011) |
Katsuaki Kanbe [Japon] ; Atsushi Nakamura [Japon] ; Yasuo Inoue [Japon] ; Kaori Hobo [Japon] | Osteoprotegerin expression in bone marrow by treatment with tocilizumab in rheumatoid arthritis |
| 000014 (2012) |
Seiji Ohtori [Japon] ; Masayuki Miyagi [Japon] ; Yawara Eguchi [Japon] ; Gen Inoue [Japon] ; Sumihisa Orita [Japon] ; Nobuyasu Ochiai [Japon] ; Shunji Kishida [Japon] ; Kazuki Kuniyoshi [Japon] ; Junichi Nakamura [Japon] ; Yasuchika Aoki [Japon] ; Tetsuhiro Ishikawa [Japon] ; Gen Arai [Japon] ; Hiroto Kamoda [Japon] ; Miyako Suzuki [Japon] ; Masashi Takaso [Japon] ; Takeo Furuya [Japon] ; Gou Kubota [Japon] ; Yoshihiro Sakuma [Japon] ; Yasuhiro Oikawa [Japon] ; Tomoaki Toyone [Japon] ; Kazuhisa Takahashi [Japon] | Efficacy of epidural administration of anti-interleukin-6 receptor antibody onto spinal nerve for treatment of sciatica |
| 000015 (2013) |
Jörg Kaufmann [Allemagne] ; Eugen Feist [Allemagne] ; Anne-Eve Roske [Allemagne] ; Wolfgang A. Schmidt [Allemagne] | Monotherapy with tocilizumab or TNF-alpha inhibitors in patients with rheumatoid arthritis: efficacy, treatment satisfaction, and persistence in routine clinical practice |
| 000016 (2009) |
Mao Mao An [République populaire de Chine] ; Zui Zou [République populaire de Chine] ; Hui Shen [République populaire de Chine] ; Jun Dong Zhang [République populaire de Chine] ; Yong Bing Cao [République populaire de Chine] ; Yuan Ying Jiang [République populaire de Chine] | The addition of tocilizumab to DMARD therapy for rheumatoid arthritis: a meta-analysis of randomized controlled trials |
| 000023 (2009) |
Misato Hashizume [Japon] ; Yasushi Uchiyama [Japon] ; Naoto Horai [Japon] ; Naohisa Tomosugi [Japon] ; Masahiko Mihara [Japon] | Tocilizumab, a humanized anti-interleukin-6 receptor antibody, improved anemia in monkey arthritis by suppressing IL-6-induced hepcidin production |
| 000025 (2014) |
Shuji Ohta [Japon] ; Tomomi Tsuru [Japon] ; Kimio Terao [Japon] ; Seiji Mogi [Japon] ; Midori Suzaki [Japon] ; Eisuke Shono [Japon] ; Yoshimasa Ishida [Japon] ; Eriko Tarumi [Japon] ; Masato Imai [Japon] | Mechanism‐based approach using a biomarker response to evaluate tocilizumab subcutaneous injection in patients with rheumatoid arthritis with an inadequate response to synthetic DMARDs (MATSURI study) |
| 000029 (2011) |
Satoru Shinriki [Japon] ; Hirofumi Jono [Japon] ; Mitsuharu Ueda [Japon] ; Kazutoshi Ota [Japon] ; Tomoko Ota [Japon] ; Takanao Sueyoshi [Japon] ; Yuichi Oike [Japon] ; Mutsuko Ibusuki [Japon] ; Akimitsu Hiraki [Japon] ; Hideki Nakayama [Japon] ; Masanori Shinohara [Japon] ; Yukio Ando [Japon] | Interleukin‐6 signalling regulates vascular endothelial growth factor‐C synthesis and lymphangiogenesis in human oral squamous cell carcinoma |
| 000031 (2005) |
Shumpei Yokota [Japon] ; Takako Miyamae [Japon] ; Tomoyuki Imagawa [Japon] ; Shigeki Katakura [Japon] ; Rumiko Kurosawa [Japon] ; Masaaki Mori [Japon] | Clinical study of tocilizumab in children with systemic-onset juvenile idiopathic arthritis |
| 000038 (2016) |
Tristan Pascart [France, Niger] ; Peggy Philippe [France] ; Elodie Drumez [France] ; Xavier Deprez [France] ; Bernard Cortet [France] ; Alain Duhamel [France] ; Eric Houvenagel [France] ; René-Marc Flipo [France] | Comparative efficacy of tocilizumab, abatacept and rituximab after non‐TNF inhibitor failure: results from a multicentre study |
| 000041 (2014) |
P. Jayasekera [Royaume-Uni] ; R. Parslew [Royaume-Uni] ; A. Al-Sharqi [Royaume-Uni] | A case of tumour necrosis factor‐α inhibitor‐ and rituximab‐induced plantar pustular psoriasis that completely resolved with tocilizumab |
| 000048 (2012) |
Hiroki Wakabayashi [Japon] ; Masahiro Hasegawa [Japon] ; Yosuke Nishioka [Japon] ; Yukari Minami [Japon] ; Kusuki Nishioka [Japon] ; Akihiro Sudo [Japon] | Clinical outcome in patients with rheumatoid arthritis switched to tocilizumab after etanercept or infliximab failure |
| 000049 (2012) |
Hubert De Boysson [France] ; Jérome Février [France] ; Amélie Nicolle [France] ; Christophe Auzary [France] ; Loïk Geffray [France] | Tocilizumab in the treatment of the adult-onset Still's disease: current clinical evidence |
| 000051 (2008) |
Atsushi Taga [Japon] ; Soichiro Kita ; Kaori Nishiura [Japon] ; Tomonori Hayashi [Japon] ; Mitsuhiro Kinoshita ; Atsushi Sato [Japon] ; Kentaro Suzuki [Japon] ; Shuji Kodama [Japon] ; Kazuaki Kakehi | Analysis of an antibody pharmaceutical, tocilizumab, by capillary electrophoresis using a carboxylated capillary |
| 000066 (2013) |
Kanae Tani [Japon] ; Risa Takayanagi [Japon] ; Haruko Yokoyama [Japon] ; Yasuhiko Yamada [Japon] | Theoretical analysis of efficacy of biological agent for rheumatoid arthritis based on target molecular binding occupancy |
| 000069 (2016) |
Nozomu Yanaihara [Japon] ; Yukihiro Hirata [Japon] ; Noriko Yamaguchi [Japon] ; Yukiko Noguchi [Japon] ; Misato Saito [Japon] ; Chie Nagata [Japon] ; Satoshi Takakura [Japon] ; Kyosuke Yamada [Japon] ; Aikou Okamoto [Japon] | Antitumor effects of interleukin‐6 (IL‐6)/interleukin‐6 receptor (IL‐6R) signaling pathway inhibition in clear cell carcinoma of the ovary |
| 000076 (2011) |
Makoto Hirao [Japon] ; Naomi Yamasaki [Japon] ; Hiroki Oze [Japon] ; Kosuke Ebina [Japon] ; Akihide Nampei [Japon] ; Yoshitaka Kawato [Japon] ; Kenrin Shi [Japon] ; Hideki Yoshikawa [Japon] ; Norihiro Nishimoto [Japon] ; Jun Hashimoto [Japon] | Serum level of oxidative stress marker is dramatically low in patients with rheumatoid arthritis treated with tocilizumab |
| 000083 (2012) |
Yasuhiko Hirabayashi [Japon] ; Tomonori Ishii [Japon] | The DAS28-ESR cutoff value necessary to achieve remission under the new Boolean-based remission criteria in patients receiving tocilizumab |
| 000088 (2011) |
Emily Beth Devine [États-Unis] ; Rafael Alfonso-Cristancho [États-Unis] ; Sean D. Sullivan [États-Unis] | Effectiveness of Biologic Therapies for Rheumatoid Arthritis: An Indirect Comparisons Approach |
| 000089 (2013) |
Alfredo Adán [Espagne] ; Marina Mesquida [Espagne] ; Victor Llorenç [Espagne] ; Gerard Espinosa [Espagne] ; Blanca Molins [Espagne] ; Maria V. Hernández [Espagne] ; Laura Pelegrín [Espagne] | Tocilizumab treatment for refractory uveitis-related cystoid macular edema |
| 000094 (2011) |
Maasa Hama [Japon] ; Takeaki Uehara [Japon] ; Kaoru Takase [Japon] ; Atsushi Ihata [Japon] ; Atsuhisa Ueda [Japon] ; Mitsuhiro Takeno [Japon] ; Kazuya Shizukuishi [Japon] ; Ukihide Tateishi [Japon] ; Yoshiaki Ishigatsubo [Japon] | Power Doppler ultrasonography is useful for assessing disease activity and predicting joint destruction in rheumatoid arthritis patients receiving tocilizumab—preliminary data |
